Kessler Topaz Meltzer & Check, LLP Reminds BTAI Investors of September 5, 2023 Deadline in Securities Fraud Class Action against of BioXcel Therapeutics, Inc. and Urges Investors with Substantial Losses to Contact the Firm
The action charges BioXcel with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
- The action charges BioXcel with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
- As a result of BioXcel’s materially misleading statements and omissions to the public, BioXcel’s investors have suffered significant losses.
- We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
- Kessler Topaz Meltzer & Check, LLP encourages BioXcel investors who have suffered significant losses to contact the firm directly to acquire more information.